TuHURA Biosciences wins new US patent covering VISTA inhibitor TBS — 2025
Tuhura Biosciences received a new U.S. patent covering its VISTA-inhibiting antibody TBS-2025. Protection expands to antibody fragments, framework or Fc modifications, bispecific or multi-specific formats across human antibody classes. Claims also cover use as monotherapy or in combination regimens, including with PD-1